Skip to main content
Premium Trial:

Request an Annual Quote

Fluorotechnics Rebrands as Gelcompany

NEW YORK (GenomeWeb News) – Fluorotechnics, a Sydney, Australia-based supplier of fluorescence and other protein detection technologies, today said that it has rebranded itself under the name of a firm it acquired last year, Gelcompany.

Fluorotechnics will continue to be the name of the holding company and it will still trade on the Australian Stock Exchange under the Fluorotechnics name and the "FLS" ticker symbol.

Fluorotechnics, which went public in October, raising nearly AUS$8 million (US$5 million), acquired San Francisco-based Gel Company, last year. GelCo provides a variety of products for applications in DNA sequencing, proteomics, cell culture, liquid handling, microarray, and PCR.

That acquisition had followed its purchase the year before of German firm Elektrophorese-Technik.

"Combining the trading and brand names for the three parts of the enterprise reflects the orientation to provide complete solutions rather than off the shelf products from different companies in different countries," Fluorotechnics CEO Duncan Veal said in a statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.